The Value of Addressing Patient Preferences

被引:21
作者
Allen, Jeff D. [1 ]
Stewart, Mark D. [1 ]
Roberts, Samantha A. [1 ]
Sigal, Ellen V. [1 ]
机构
[1] Friends Canc Res, 1800 M St NW,Suite 1050 South, Washington, DC 20036 USA
关键词
assessment; breakthrough therapies; cancer; value framework; ONCOLOGY; THERAPIES; SURVIVAL; SOCIETY; TRIALS; DRUGS;
D O I
10.1016/j.jval.2016.11.029
中图分类号
F [经济];
学科分类号
02 ;
摘要
Recent scientific progress is, in some cases, leading to transformative new medicines for diseases that previously had marginal or even no treatment options. This offers great promise for people affected by these diseases, but it has also placed stress on the health care system in terms of the growing cost associated with some new interventions. Effort has been taken to create tools to help patients and health care providers assess the value of new medical innovations. These tools may also provide the basis for assessing the price associated with new medical products. Given the growing expenditures in health care, value frameworks present an opportunity to evaluate new therapeutic options in the context of other treatments and potentially lead to a more economically sustainable health care system. In summary, the contribution to meaningful improvements in health outcomes is the primary focus of any assessment of the value of a new intervention. A component of such evaluations, however, should factor in timely access to new products that address an unmet medical need, as well as the magnitude of that beneficial impact. To achieve these goals, value assessment tools should allow for flexibility in clinical end points and trial designs, incorporate patient preferences, and continually evolve as new evidence, practice patterns, and medical progress advance.
引用
收藏
页码:283 / 285
页数:3
相关论文
共 13 条
[1]  
[Anonymous], 2010, CLIN DAT BAS TAPL HL, DOI DOI 10.17226/12212
[2]   Utility of Cancer Value Frameworks for Patients, Payers, and Physicians [J].
Chandra, Amitabh ;
Shafrin, Jason ;
Dhawan, Ravinder .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (19) :2069-2070
[3]   A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) [J].
Cherny, N. I. ;
Sullivan, R. ;
Dafni, U. ;
Kerst, J. M. ;
Sobrero, A. ;
Zielinski, C. ;
de Vries, E. G. E. ;
Piccart, M. J. .
ANNALS OF ONCOLOGY, 2015, 26 (08) :1547-1573
[4]   Conducting Phase IV clinical studies: a moral imperative? [J].
Hill, T. P. .
ECANCERMEDICALSCIENCE, 2012, 6
[5]  
Institute for Clinical and Economic Review, EV VAL NEW DRUGS DEV
[6]   Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation [J].
Jonsson, Linus ;
Sandin, Rickard ;
Ekman, Mattias ;
Ramsberg, Joakim ;
Charbonneau, Claudie ;
Huang, Xin ;
Jonsson, Bengt ;
Weinstein, Milton C. ;
Drummond, Michael .
VALUE IN HEALTH, 2014, 17 (06) :707-713
[7]   Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies [J].
Korn, Edward L. ;
Freidlin, Boris ;
Abrams, Jeffrey S. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2439-2442
[8]  
Lu Y, 2012, AM J MANAG CARE, V18, pS249
[9]  
*NAT COMPR CANC NE, NCCN CLIN PRACT GUID
[10]   Measuring the Value of Prescription Drugs [J].
Neumann, Peter J. ;
Cohen, Joshua T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) :2595-2597